Advances in medicine have made it possible to utilize the healing properties of ketamine through controlled clinical administration. Spravato, an esketamine-based nasal spray, is highly effective in the treatment of depression and suicidal ideation, especially for those who have not had success with traditional methods.
Spravato is emerging as an advanced treatment with a high success rate, and many people have questions about what Spravato is and how it can benefit them. Our dedicated team at Upswing Psychiatry is here to help you understand what to expect from your Spravato treatments by answering some Spravato FAQs. Contact us today to schedule your initial consultation and get started.
Individuals commonly ask whether the FDA has fully cleared Spravato for treatment-resistant depression and suicidal ideation in adults. In 2019, the FDA cleared Spravato as an add-on therapy to oral antidepressants, and in 2025, approval was expanded to clear Spravato as a monotherapy, allowing clinicians to use it independently to treat depressive symptoms in patients who have not responded well to antidepressants.
Spravato has undergone several studies to answer key questions about its ability to treat symptoms of depression quickly and effectively. Research shows that 88 percent of patients experienced a significant reduction in depressive symptoms after three months of Spravato use, with some experiencing complete relief. Studies show that this esketamine-based nasal spray is most effective when clinicians follow a phase-based dosing schedule, starting with more frequent treatments that decrease over time.
Patients also ask whether Spravato offers rapid relief for those experiencing depressive or suicidal thoughts. Most individuals report symptom relief within just 24 hours after their first Spravato dose, with effects continuing to improve over time. The fast-acting nature of this esketamine-based nasal spray makes it a unique option for individuals experiencing an acute emotional crisis who need rapid symptom improvement.
Another commonly asked question involves whether you can drive home after your Spravato treatment. Spravato contains esketamine, a medication with sedative effects. As a result, some patients may experience short-term drowsiness, dizziness, or a sense of dissociation during or after treatment. Because of these potential effects, patients must arrange reliable transportation home following each Spravato session.
Many individuals wonder if Spravato is the right treatment for them. If you are an adult in good overall health with treatment-resistant depression or suicidal ideation, you may be a candidate for Spravato. You may not be eligible for this nasal spray if you have certain cardiovascular conditions, such as uncontrolled high blood pressure or aneurysms, a history of brain bleeds, or are pregnant or breastfeeding. Spravato can cause temporary spikes in blood pressure that may not be safe for individuals with cardiac conditions and may not be a suitable treatment option for those with a history of substance abuse.
The best way to know if you are a candidate for Spravato is by scheduling an initial evaluation at our office. One of our board-certified psychiatry providers will ask you questions about your medical and psychiatric history and current mental health needs. We can then perform an initial mental health evaluation, determine your eligibility for treatment, and begin scheduling you for your initial Spravato sessions.
Spravato provides an empowering way to take control of your mental health and find long-awaited relief from symptoms of depression. Struggling with your mental health can impact every aspect of life, and with Spravato, newfound wellness is possible. If you have more questions after reading these Spravato FAQs, our team is here to provide clarity about this advanced treatment. Contact us today to speak with a member of our team.